

APPLICANT(S): WALDMANN, Herman et al.
SERIAL NO.: 09/849,499
FILED: May 4, 2001
Page 2

In the Specification:

Please insert the following paragraph and headings after the Title of the invention:

--Cross Reference to Related Applications

This application is a continuation of co-pending International Patent Application Number PCT/GB99/03653, filed November 5, 1999 and claims priority from GB Patent Application Number 9824306.6 filed November 5, 1998. The entire content of the prior applications is incorporated herein by reference.

Field of the Invention--

Please insert on page 4 the following headings and paragraph instead the words "The invention":

--Brief Description of the Drawings:

Figure 1 shows phase-contrast micrographs of ES cell derived DC (esDC);

Figure 2 shows electron micrographs of esDC cultured in GM-CSF and IL-3;

Figure 3 shows surface phenotype of esDC grown in GM-CSF and IL-3 assessed by flow cytometry;

Figure 4 shows immunostimulatory activity of esDC in an allogeneic mixed leukocyte reaction;

Figure 5 shows IL-2 secretion by T cells in response to antigen presentation by esDC, and inhibition of IL-2 secretion by a mAb to MHC class II;

Figure 6 shows flow cytometric analysis of esDC following maturation induced by the addition of lipopolysaccharide (LPS) to cultures;

Figure 7 shows immunostimulatory activity of LPS-treated esDC;

Figure 8 shows immunostimulatory activity by myeloid and lymphoid esDC;

Figure 9 shows antigen processing activity of myeloid and lymphoid esDC; and

Figure 10 shows the generation of esDC stably transfected with GFP following introduction of the transgene into the parent ES cell line.